With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.215309-01-6,3-(4-Methylpiperazin-1-yl)benzoic acid,as a common compound, the synthetic route is as follows.
Example 33: lambdaP-(2<:yano-9-methyl-9Hphiurin-6-yl)-lambdaP<:yclopentyl-3-(4-methyl-1 - piperazinyl)benzohydrazide trifluoroacetate.Intermediate 51 (2 g, 9.08 mmol) was dissolved in oxalyl chloride (2OmL) and the mixture was stirred overnight. The solvent was removed under reduced pressure and part of the residue (1.1 g, 4.64 mmol) was added to a solution of Intermediate 16 (300 mg, 1.16 mmol) and DIPEA (FLUKA, 0.794 mL, 4.64 mmol) in THF (50 mL). Potassium tert- butoxide (ALDRICH, 260 mg, 2.32 mmol) was added and the mixture was stirred at rt for 1 day. The solvent was removed under reduced pressure and the crude was purified by preparative HPLC (SUNFIRE 30x150mm, ACN:H2O 0.1%TFA, gradient 10%-100%) to yield the title compound. 1H NMR (300 MHz, DMSO-d6, 8O0C) delta ppm: 10.70 (s, 1 H), 8.27
The synthetic route of 215309-01-6 has been constantly updated, and we look forward to future research findings.
Reference：
Patent; GLAXO GROUP LIMITED; WO2008/107368; (2008); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics